Abstracts for HPN217 and HPN328 accepted for presentations at the International Myeloma Society (IMS) Annual Meeting and the European Society for Medical Oncology (ESMO) in the fall
Enrollment for HPN328 (DLL3) ongoing; Phase 2 dose selection expected by year end
Completed planned enrollment for HPN217 Phase 1 trial in relapsed/refractory multiple myeloma patients; data presentation and selection of Phase 2 dose expected by year end
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
“Following successful completion of the planned Phase 1 enrollment in the HPN217 trial, we are eager to reach additional important milestones in 2023,” said Julie Eastland, President and CEO of Harpoon Therapeutics. “We are on track to present data from our two TriTAC clinical programs later this year at leading medical conferences and select the Phase 2 monotherapy regimens for both HPN217 and HPN328. Harpoon’s financial resources are expected to fund current operations into the second half of 2024 and we remain focused on advancing our key programs.”
Corporate Update / Recent Highlights and Upcoming Milestones
Tri-specific T cell Activating Construct (TriTAC®) Platform
HPN217 (BCMA) Phase 1 trial for relapsed, refractory multiple myeloma
HPN328 (DLL3) Phase 1/2 trial in small cell lung cancer (SCLC) and other neuroendocrine cancers
ProTriTAC™
HPN601 (EpCAM)
TriTAC-XR®
Corporate Update
Second Quarter 2023 Financial Results
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “can,” “expect,” “plan,” “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the expected progress, results, and plans pertaining to Harpoon Therapeutics’ clinical trials, including timing, scope, design and interim results of clinical trials and the safety and tolerability profile of product candidates, the association of interim clinical data and preclinical results with potential treatment outcomes, achievement of future milestones, cash sufficiency forecasts, and other statements that are not historical fact. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, preliminary data and trends may not be predictive of future data or results, may not demonstrate safety or efficacy or lead to regulatory approval by the FDA or other regulatory agencies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, the timing and results of unexpected litigation or other disputes, and the sufficiency of Harpoon Therapeutics’ cash resources, including that Harpoon Therapeutics may not achieve the expected benefits of its restructuring or may incur unexpected additional expenses in connection with such restructuring. These and other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including under “Risk Factors” in Harpoon Therapeutics’ quarterly report on Form 10-Q for the quarter ended June 30, 2023, and future filings by Harpoon Therapeutics. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contacts:
Investors and media:
ICR Westwicke
Robert H. Uhl
619-228-5886
[email protected]
Harpoon Therapeutics, Inc. Statement of Operations and Comprehensive Income (Loss) (Unaudited) (in thousands, except share and per share amounts) | |||||||||||||||
For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
Revenue | |||||||||||||||
Collaboration and license revenue | $ | 20,221 | $ | 8,303 | $ | 28,804 | $ | 14,209 | |||||||
Total revenue | 20,221 | 8,303 | 28,804 | 14,209 | |||||||||||
Operating expenses | |||||||||||||||
Research and development | 12,196 | 20,651 | 27,359 | 41,469 | |||||||||||
General and administrative | 3,803 | 5,063 | 7,988 | 10,464 | |||||||||||
Impairment of long-live assets | 1,729 | — | 1,729 | — | |||||||||||
Total operating expenses | 17,728 | 25,714 | 37,076 | 51,933 | |||||||||||
Income (loss) from operations | 2,493 | (17,411 | ) | (8,272 | ) | (37,724 | ) | ||||||||
Interest income, net | 615 | 104 | 1,040 | 144 | |||||||||||
Interest expense | (1,560 | ) | — | (1,698 | ) | — | |||||||||
Other expense, net | (488 | ) | (44 | ) | (1,347 | ) | (92 | ) | |||||||
Net income (loss) attributable to common stockholders | 1,061 | (17,351 | ) | (10,277 | ) | (37,672 | ) | ||||||||
Other comprehensive income (loss) | |||||||||||||||
Net unrealized gain (loss) on marketable securities | 5 | 32 | 8 | (9 | ) | ||||||||||
Comprehensive income (loss) | $ | 1,066 | $ | (17,319 | ) | $ | (10,269 | ) | $ | (37,681 | ) | ||||
Net income (loss) attributable to common stockholders per share, basic | $ | 0.03 | $ | (0.53 | ) | $ | (0.28 | ) | $ | (1.14 | ) | ||||
Net income (loss) attributable to common stockholders per share, diluted | $ | 0.03 | $ | (0.53 | ) | $ | (0.28 | ) | $ | (1.14 | ) | ||||
Weighted-average shares used in computing net income (loss) per share, basic | 37,671,883 | 33,036,873 | 37,321,992 | 32,958,711 | |||||||||||
Weighted-average shares used in computing net income (loss) per share, diluted | 37,972,990 | 33,036,873 | 37,321,992 | 32,958,711 | |||||||||||
Harpoon Therapeutics, Inc. Selected Balance Sheet Data (Unaudited) | ||||||
June 30, 2023 | December 31, 2022 | |||||
(in thousands) | ||||||
Cash, cash equivalents, and marketable securities | $ | 45,555 | $ | 53,112 | ||
Total assets | $ | 63,199 | $ | 73,729 | ||
Total liabilities | $ | 60,201 | $ | 68,330 | ||
Total stockholders' equity | $ | 2,998 | $ | 5,399 |
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member